Dr. Lane Christensen is an Assistant Country Director of the China Office in the Office of International Programs (OIP) at the US Food and Drug Administration (FDA) where he serves as the International Program and Policy Analyst (IPPA) for Drugs. Before joining the FDA China Office, he was a Branch Chief in the Office of Process and Facilities (OPF), in the Office of Pharmaceutical Quality (OPQ), CDER, FDA which is tasked with the review of manufacturing process and established facility inspections for abbreviated and new drug applications (A/NDAs).
Previously he was with the Office of Generic Drugs (OGD) as a Team Leader in a review division and as a Chemist with the Immediate Office having various responsibilities related to Chemistry Manufacturing Control activities such as ANDA review, Control Correspondences, Citizen Petitions, and policy development. Lane was extensively involved in various initiatives related to OPQ reorganization and new user fee implementation under GDUFA including the lead for hiring efforts and involvement with risk-based review efforts. He received his Ph.D. in Pharmaceutics and Pharmaceutical Chemistry from the University of Utah followed by a post-doctoral fellowship within the pharmaceutical industry. Lane began his FDA career with the CDRH Office of Compliance.